Methods of reduction of interpatient variability
AssigneeAuspex Pharmaceuticals, Inc.
InventorsThomas G. Gant, Sepehr Sarshar
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for the reduction of inter-patient variability of a drug, such as in one or more parameters including half-life (t1/2), maximum plasma concentration (Cmax), time at maximal plasma concentration (Tmax), area under the time-versus-concentration curve (AUC). Also provided are methods of reducing side effects associated with drugs.
Claims25
A method of reducing inter-patient variability in a drug treatment, comprising;
- i. identifying inter-patient variability in said drug treatment;
- ii. preparing a deuterated analog of said drug;
- and
- iii. using said deuterated analog in said drug treatment to reduce inter-patient variability of said drug treatment.
A method of reducing interpatient variability in a population of patients taking a drug comprising
- i. identifying a population of patients having interpatient variability;
- and
- ii. administering to a population of patients a deuterated analog of a drug.
A deuterated analog of venlafaxine having a reduced inter-patient variability in plasma half life of 20% or more compared to non-deuterated venlafaxine.
A deuterated analog of venlafaxine having a reduced inter-patient variability in maximum plasma concentration in humans of 30% or more compared to non-deuterated venlafaxine.
A deuterated analog of venlafaxine having a reduced inter-patient variability in maximum plasma concentration in humans of 40% or more compared to non-deuterated venlafaxine.
A deuterated analog of venlafaxine having a reduced inter-patient variability time at maximal plasma concentration in humans of 15% or more compared to non-deuterated venlafaxine.
A deuterated analog of venlafaxine having a reduced inter-patient variability in plasma area under the time-versus-concentration curve 20% or more compared to non-deuterated venlafaxine.
A deuterated analog of venlafaxine which causes at least 25% fewer side effects than non-deuterated venlafaxine.
Dependencies are inferred from the claim text.